An anti-BCMA ADC conjugated to MMAF (belantamab mafodotin) was shown to be beneficial in patients with multiple myeloma in clinical studies and became the first BCMA-targeting ADC to receive accelerated approval from the FDA as monotherapy in 2020. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.